Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

afuresertib

An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Cancer is a devastating disease that has plagued humans from ancient times to this day. After decades of slow research progress… Expand
2019
2019
Abstract AKT plays a centralized role in tumor proliferation and survival and is aberrantly activated in chronic lymphocytic… Expand
2018
2018
Purpose: Preclinically, AKT kinase inhibition restores drug sensitivity in platinum-resistant tumors. Here the pan-AKT kinase… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
2018
2018
Afuresertib (AFU), a novel inhibitor of the serine/threonine kinase AKT, has clinical efficacy as a monotherapy against… Expand
  • figure 1
  • figure 2
  • figure 3
2017
2017
Malignant pleural mesothelioma (MPM), an asbestos‐related occupational disease, is an aggressive and incurable tumor of the… Expand
2017
2017
Langerhans cell histiocytosis (LCH) is a clonal neoplasm characterized by widely varied clinical presentations, including… Expand
2015
2015
Background Dual targeting of overlapping pathways in hematologic malignancies is an attractive therapeutic strategy to prevent… Expand
Highly Cited
2014
Highly Cited
2014
PurposeTo identify the maximum tolerated dose (MTD) and recommended Phase II dose of MEK/AKT inhibitor combination of trametinib… Expand
  • table 1
  • table 2
Highly Cited
2014
Highly Cited
2014
The PI3K/AKT pathway is constitutively active in hematologic malignancies, providing proliferative and antiapoptotic signals and… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
2013
2013
Background Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models… Expand